Insights

Expanding R&D Footprint BioNTech has announced significant investments in the UK, including the development of new drug research facilities and an AI hub, indicating a focus on next-generation medicine development and technology integration that could require specialized collaborations and supply chain support.

Strategic Workforce Adjustments With planned layoffs of up to 950 employees across Europe and North America by 2027, BioNTech may be open to partnerships offering talent acquisition solutions, outsourcing, or consultancy services to optimize operational efficiencies.

Focus on Oncology Innovation BioNTech actively showcases advancements in its oncology pipeline at major industry events, presenting opportunities to connect with their R&D teams for early-stage collaborations, joint ventures, or technology licensing in cancer immunotherapy.

Market Post-Pandemic Strategy Post-COVID market adjustments and a shift in focus towards infectious diseases and oncology could open doors for partners providing specialized vaccines, infectious disease therapies, or market expansion support tailored to these sectors.

Financial Growth Potential With revenues ranging from one to ten billion dollars and recent investments, BioNTech is a high-growth company likely seeking innovative solutions in biotech, AI, manufacturing, and healthcare analytics, creating opportunities for technology vendors and service providers targeting biotech expansion.

BioNTech SE Tech Stack

BioNTech SE uses 8 technology products and services including SAS/GRAPH, Monte Carlo, SuccessFactors, and more. Explore BioNTech SE's tech stack below.

  • SAS/GRAPH
    Business Intelligence
  • Monte Carlo
    Data Management Platforms
  • SuccessFactors
    Human Resource Management System
  • LinkedIn
    Online Community Software
  • macOS
    Operating Systems & Computing Languages
  • Yoast SEO
    Search Engines
  • Friendly Captcha
    Security
  • Twitter
    Widgets

Media & News

BioNTech SE's Email Address Formats

BioNTech SE uses at least 1 format(s):
BioNTech SE Email FormatsExamplePercentage
First.Last@biontech.deJohn.Doe@biontech.de
90%
FLast@biontech.deJDoe@biontech.de
6%
LF@biontech.deDJ@biontech.de
2%
First.Middle@biontech.deJohn.Michael@biontech.de
2%

Frequently Asked Questions

What is BioNTech SE's phone number?

Minus sign iconPlus sign icon
You can contact BioNTech SE's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is BioNTech SE's stock symbol?

Minus sign iconPlus sign icon
BioNTech SE is a publicly traded company; the company's stock symbol is BNTX.

What is BioNTech SE's official website and social media links?

Minus sign iconPlus sign icon
BioNTech SE's official website is biontech.de and has social profiles on LinkedInCrunchbase.

How much revenue does BioNTech SE generate?

Minus sign iconPlus sign icon
As of December 2025, BioNTech SE's annual revenue is estimated to be $18B.

What is BioNTech SE's SIC code NAICS code?

Minus sign iconPlus sign icon
BioNTech SE's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does BioNTech SE have currently?

Minus sign iconPlus sign icon
As of December 2025, BioNTech SE has approximately 5K employees across 6 continents, including EuropeNorth AmericaAsia. Key team members include Chief Executive Officer & Co-Founder: U. S.Chief Financial Officer: R. Z.Chief Of Staff To Cco: M. P.. Explore BioNTech SE's employee directory with LeadIQ.

What industry does BioNTech SE belong to?

Minus sign iconPlus sign icon
BioNTech SE operates in the Biotechnology Research industry.

What technology does BioNTech SE use?

Minus sign iconPlus sign icon
BioNTech SE's tech stack includes SAS/GRAPHMonte CarloSuccessFactorsLinkedInmacOSYoast SEOFriendly CaptchaTwitter.

What is BioNTech SE's email format?

Minus sign iconPlus sign icon
BioNTech SE's email format typically follows the pattern of First.Last@biontech.de. Find more BioNTech SE email formats with LeadIQ.

How much funding has BioNTech SE raised to date?

Minus sign iconPlus sign icon
As of December 2025, BioNTech SE has raised $145M in funding. The last funding round occurred on May 29, 2024 for $145M.

When was BioNTech SE founded?

Minus sign iconPlus sign icon
BioNTech SE was founded in 2008.

BioNTech SE

Biotechnology ResearchRhineland-palatinate, Germany5001-10000 Employees

Biopharmaceutical New Technologies (BioNTech) is a global biotechnology company aspiring to translate science into survival by developing new immunotherapies utilizing the full potential of the immune system to fight cancer and infectious diseases. 

BioNTech is headquartered in Mainz, Germany, and operates globally with almost 7.000 pioneers. Our work is powered by one mission: Improving the health of people worldwide. We believe that scientific rigor and passion are the driving forces that are essential for innovative progress.  

BioNTech was founded in 2008 by scientists and physicians to translate science into survival by combining fundamental research and operational excellence. At BioNTech, we have been conducting fundamental research of mRNA technologies in the field of individualized cancer medicine for more than a decade. Some of our colleagues, including our co-founders, have been researching and developing mRNA-based vaccines for more than 25 years. 

Ready to join us on this journey? Explore the opportunities and become part of a team that aspires to turn bold ideas into real-world solutions: https://www.biontech.com/int/en/home/careers.html

🔗 Privacy Statement: https://www.biontech.com/int/en/home/data-privacy-statement.html  
 
🔗 Imprint: https://www.biontech.com/int/en/home/imprint.html

Section iconCompany Overview

Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
BNTX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2008
Employees
5001-10000

Section iconFunding & Financials

  • $145M

    BioNTech SE has raised a total of $145M of funding over 10 rounds. Their latest funding round was raised on May 29, 2024 in the amount of $145M.

  • $1B$10B

    BioNTech SE's revenue is estimated to be in the range of $1B$10B

Section iconFunding & Financials

  • $145M

    BioNTech SE has raised a total of $145M of funding over 10 rounds. Their latest funding round was raised on May 29, 2024 in the amount of $145M.

  • $1B$10B

    BioNTech SE's revenue is estimated to be in the range of $1B$10B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.